1. Home
  2. ESPR vs HTD Comparison

ESPR vs HTD Comparison

Compare ESPR & HTD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.39

Market Cap

898.5M

Sector

Health Care

ML Signal

HOLD

Logo John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

HTD

John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

HOLD

Current Price

$24.97

Market Cap

843.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESPR
HTD
Founded
2008
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
898.5M
843.6M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ESPR
HTD
Price
$3.39
$24.97
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$6.67
N/A
AVG Volume (30 Days)
5.3M
92.3K
Earning Date
03-03-2026
01-01-0001
Dividend Yield
N/A
8.59%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$303,802,000.00
N/A
Revenue This Year
$27.49
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.83
N/A
52 Week Low
$0.69
$16.17
52 Week High
$4.18
$22.13

Technical Indicators

Market Signals
Indicator
ESPR
HTD
Relative Strength Index (RSI) 48.87 64.34
Support Level $3.16 $24.70
Resistance Level $3.64 $24.90
Average True Range (ATR) 0.21 0.30
MACD 0.01 0.07
Stochastic Oscillator 61.94 86.90

Price Performance

Historical Comparison
ESPR
HTD

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, communication services, materials, healthcare, real estate, consumer Staples, and short-term investments.

Share on Social Networks: